Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine (CARDIO BIO-MAP)

3. november 2026 oppdatert av: Weill Cornell Medical College in Qatar

Determination of Specificity and Sensitivity in Detecting Myocardial Infarction Using the EDE CARDIO BIO-MAP Machine, the EDE CARDIO BIO-MAP Study

The goal of this observational study is to learn whether a non-invasive electromagnetic wave scanner (EDE CARDIO BIO-MAP) can help diagnose myocardial infarction (heart attack) in adults (18 years and older) who come to the emergency department with chest pain and suspected myocardial infarction. The main questions it aims to answer are:

  • How sensitive and specific is the EDE scanner in diagnosing myocardial infarction (MI) compared with standard blood tests (e.g., cardiac troponin)?
  • How sensitive and specific are the immediate blood measurements from a portable lab device compared with conventional hospital laboratory measurements? Researchers will compare the results of the EDE scanner and the portable lab with standard hospital blood test results and the final clinical diagnosis to see how accurately each detects MI.

Participants will:

  • Have a research visit (30 minutes to 1 hour) during their emergency care, including a quick scan with the Exponential Deep Examination (EDE) device (attached to a phone or tablet) and a small research blood sample tested on a portable lab device
  • Repeat the scan and blood sample 4 to 6 hours later, only if a second blood draw is already needed for their clinical care
  • Answer questions about their medical and social history, and allow the study team to collect relevant results from their medical record Scanner results will not be shared with participants or used for their clinical care.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Detaljert beskrivelse

Myocardial infarction is a leading cause of death and disability worldwide. Current diagnosis relies on clinical assessment, electrocardiogram, and blood measurement of cardiac biomarkers such as troponin. Faster, non-invasive diagnostic tools could be especially valuable in the emergency setting, where timely intervention is critical.

The Exponential Deep Examination Cardio Bio-Map is a non-invasive device, classified as Class 1 under the European Conformity marking system, that analyzes passive electromagnetic signals (0.1 to 300 gigahertz) using artificial intelligence to measure cardiac biomarkers without a blood draw. Results are available within 50 milliseconds. The device does not collect or store patient data. It produces an immediate printed report, and all data processing occurs locally within Qatar. During the COVID-19 pandemic, the same technology detected the SARS-CoV-2 virus with a specificity of 95.62% and a sensitivity of 93.71% compared with polymerase chain reaction testing and antibody testing. This study will evaluate whether the device can screen for myocardial infarction through measurement of cardiac biomarkers, both in biological samples (in vitro, using a portable laboratory device) and directly in patients (in vivo, using the scanner).

Studietype

Observasjonsmessig

Registrering (Antatt)

200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Participants will be recruited at Hamad Medical Corporation

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years.
  • Adults presenting to the emergency room for acute chest pain.
  • English or Arabic speakers.

Exclusion Criteria:

  • Pregnancy (self-reported).
  • Adults with cognitive disorders.
  • Unconscious patients.
  • Citizens from countries where the General Data Protection Regulation (GDPR) applies, due to regulatory constraints.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sensitivity and specificity of the EDE CARDIO BIO-MAP scanner(in vivo) for detecting myocardial infarction
Tidsramme: Baseline

Sensitivity (true positives / [true positives + false negatives]) and specificity (true negatives / [true negatives + false positives]) of the scanner in emergency room patients with suspected myocardial infarction, compared with standard hospital laboratory results (cardiac troponin, creatine kinase-myocardial band, myoglobin, B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide) and the final clinical diagnosis in the medical record.
Baseline

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Sensitivity and specificity of the portable lab's immediate blood measurements (in vitro)
Tidsramme: Baseline

Sensitivity and specificity of the portable lab's immediate blood measurements for myocardial infarction, compared with conventional hospital laboratory measurements, using a confusion matrix.
Baseline
Accuracy of the EDE scanner
Tidsramme: Baseline

Accuracy = (true positives + true negatives) / all results;
Baseline
Misclassification rate of the EDE scanner
Tidsramme: Baseline

Misclassification rate = (false positives + false negatives) / all results;
Baseline
Precision of the EDE scanner
Tidsramme: Baseline

precision = true positives / (true positives + false positives)
Baseline
Accuracy of the portable lab
Tidsramme: Baseline

Accuracy = (true positives + true negatives) / all results;
Baseline
Misclassification rate of the portable lab
Tidsramme: Baseline

Misclassification rate = (false positives + false negatives) / all results;
Baseline
Precision of the portable lab
Tidsramme: Baseline

precision = true positives / (true positives + false positives)
Baseline
Correlation Between EDE Scanner and Portable Laboratory Values for Cardiac Biomarkers
Tidsramme: Baseline

Pearson or Spearman correlation coefficient between scanner and portable lab values for cardiac biomarkers : Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB.
Baseline
Predictive power of each cardiac biomarker for myocardial infarction
Tidsramme: Baseline

Logistic regression, area under the receiver operating characteristic curve, and optimal diagnostic cutoffs for each cardiac biomarker: Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB.
Baseline

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in cardiac biomarker levels between initial assessment and 4-6 hour follow-up
Tidsramme: Baseline and 4-6 hours after initial assessment

Change in cardiac biomarker levels( Troponin T, Troponin I, Myoglobin, B-type Natriuretic Peptide, NT-proBNP, and Creatine Kinase-MB) between the initial assessment and the follow-up, in participants who have a second clinical blood draw.
Baseline and 4-6 hours after initial assessment
Diagnostic performance of the scanner by sex
Tidsramme: Baseline

Subgroup analysis of scanner sensitivity and specificity by sex
Baseline
Diagnostic performance of the scanner by age group
Tidsramme: Baseline

Subgroup analysis of scanner sensitivity and specificity by age group
Baseline
Diagnostic performance of the scanner by symptom profile
Tidsramme: Baseline

Subgroup analysis of scanner sensitivity and specificity by symptom profile.
Baseline

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Weill Cornell Medical College in Qatar

Samarbeidspartnere

Hamad Medical Corporation

Etterforskere

  • Hovedetterforsker: Charbel Abi Khalil, MD,PhD, Weill Cornell Medicine-Qatar

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. juni 2029

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

22. oktober 2026

Først innsendt som oppfylte QC-kriteriene

3. november 2026

Først lagt ut (Faktiske)

9. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 23-00017

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

ongoing discussion with the sponsor

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere